Expert review of hematology · 2026
Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review.
Систематический обзорСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vito Vitória Maria, Boff Vinícius André, Demarchi Izabel Galhardo, de Moraes Ana Carolina Rabello
Аннотация
INTRODUCTION: Acute myeloid leukemia is a hematological malignancy characterized by clonal expansion and blockade of myeloid precursor differentiation. This results in poor survival rates, particularly among older patients and those with refractory disease. CD123, the α-chain of the interleukin-3 receptor, is overexpressed in leukemic stem cells and represents a promising therapeutic target.
METHODS: This systematic review evaluated the efficacy and safety of anti-CD123 monoclonal antibodies administered as standalone treatment or in combination with standard care. The review adhered to the PRISMA statement and Cochrane Handbook.
RESULTS: Eight clinical trials (seven phase I/II trials and one phase III trial) that evaluated antibody-drug conjugates and bispecific antibodies met the inclusion criteria. The interventions demonstrated limited improvements in overall survival and showed frequent treatment-related toxicities such as cytokine release syndrome and dose-limiting adverse events. Most studies included heavily pretreated, relapsed, or refractory patients, which may have contributed to the poor tolerability and limited efficacy.
CONCLUSIONS: Future studies should focus on conducting randomized trials with larger sample sizes and greater methodological rigor to validate the clinical utility of anti-CD123 therapies, which currently have a limited impact on overall survival.
REGISTRATION: This study systematic review was prospectively registered on PROSPERO (identifier CRD4202344450.).
METHODS: This systematic review evaluated the efficacy and safety of anti-CD123 monoclonal antibodies administered as standalone treatment or in combination with standard care. The review adhered to the PRISMA statement and Cochrane Handbook.
RESULTS: Eight clinical trials (seven phase I/II trials and one phase III trial) that evaluated antibody-drug conjugates and bispecific antibodies met the inclusion criteria. The interventions demonstrated limited improvements in overall survival and showed frequent treatment-related toxicities such as cytokine release syndrome and dose-limiting adverse events. Most studies included heavily pretreated, relapsed, or refractory patients, which may have contributed to the poor tolerability and limited efficacy.
CONCLUSIONS: Future studies should focus on conducting randomized trials with larger sample sizes and greater methodological rigor to validate the clinical utility of anti-CD123 therapies, which currently have a limited impact on overall survival.
REGISTRATION: This study systematic review was prospectively registered on PROSPERO (identifier CRD4202344450.).